New drug cocktail targets cancers with faulty DNA repair

NCT ID NCT05694715

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether combining two drugs—niraparib and irinotecan—can safely treat advanced solid tumors that have mutations in DNA repair genes like BRCA. The study will enroll 24 adults with various cancers, including breast, ovarian, pancreatic, and others. The main goal is to find the safest dose and check for side effects, with a secondary look at whether the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib (Zejula) and irinotecan (Camptosar)
What this could lead to: If it works, this could point toward a new treatment option for people with certain hard-to-treat cancers that have DNA repair gene mutations.
What could go wrong: This is a very early phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. The combination may prove too toxic or not effective enough to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATM GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition metastatic malignant neoplasm Neoplasm Metastasis PALB2-related cancer predisposition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATM GENE MUTATION BRCA1 MUTATION BRCA2 MUTATION METASTATIC SOLID TUMOR PALB2 GENE MUTATION

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.